TABLE 2.
Disease name | DUBs | The role and function of DUBs | References |
---|---|---|---|
Cancer | USP3, USP4, USP5, USP7, USP11, USP14, USP17, USP27X, USP29, USP36, USP37, USP42, USP46, USP47, A20, CSN5, OTUB1, OTUD4, UCHL1 | Upregulation of epithelial–mesenchymal transition in cancer | 199 , 284 |
USP2A, USP3, USP4, USP6, USP13, USP15, USP16, USP17, USP21, USP22, USP27X, USP28, USP38, USP39, USP42, USP43, USP49, USP51, CSN5, POH1, TRABID, UCHL1, UCHL3, BRCC36, COPS6, COPS5, ATXN3L, ATXN3, OTUD7B, OTUD2 |
Upregulation of tumor invasion in cancer | 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 | |
USP9X, USP53, OTUD3 | Downregulation of tumor invasion in cancer | 199 , 284 , 300 , 301 | |
USP3, USP4, USP8, USP9X, USP17, USP22, USP27X, USP29, USP37, USP45, UCHL1 |
Upregulation of tumor migration in cancer | 199 , 284 | |
USP11, USP53 | Downregulation of tumor migration in cancer | 199 , 284 | |
USP1, USP4, USP7, USP10, USP11, USP20, USP21, USP24, USP26, USP33, A20, ataxin 3, CSN5, OTUB2, UCHL1, AMSH, COPS6, COPS5, UCHL5 |
Upregulation of metastatic dissemination in cancer | 199 , 217 , 284 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 | |
OTUD1, TRABID, OTUD7A, OTUD6B, CYLD | Downregulation of metastatic dissemination in cancer | 199 , 284 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 | |
Neurodegenerative diseases and other nervous system disorders | ATXN3, USP7, USP8, USP14, USP15, USP30, BAP1, CYLD, PSMD14, TNFAIP3, UCH‐L1, UCHL‐5, USP1, USP4, USP10, USP11, USP12, USP13, USP18, USP22, USP33, USP36, USPL1, USP9X, YOD1 | Involved in the upregulation of neurodegeneration formation | 61 , 243 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 |
USP16, A20, CYLD, OTULIN, USP18, USP25, UCHL1, UCHL3, UCHL5/UCH37, USP2, USP5, OTUD4, PSMD14, EIF3H, AMSH | Involved in the progression of other nervous system disorders | 10 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 | |
Obesity | USP2, USP7, USP15, USP19, USP20 | Involved in the progression of worsening obesity | 271 , 350 , 351 , 352 |
USP53 | Involved in the progression of reducing obesity | 271 , 353 | |
T1DM | USP18, USP22 | Involved in the progression of worsening T1DM | 275 , 277 , 350 |
T2DM | USP1, USP19, USP21, USP2, USP14, USP20 | Involved in the progression of worsening T2DM | 354 , 355 , 356 , 357 , 358 |
USP22, USP2, USP9X, USP20, USP33, USP4, USP7, USP10, USP18 | Involved in the progression of reducing T2DM | 356 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 |